| 2.2 0.27 (13.99%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.8 |
1-year : | 3.27 |
| Resists | First : | 2.4 |
Second : | 2.8 |
| Pivot price | 1.97 | |||
| Supports | First : | 1.9 |
Second : | 1.6 |
| MAs | MA(5) : | 1.99 |
MA(20) : | 1.93 |
| MA(100) : | 1.96  |
MA(250) : | 1.81 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 46.8 |
D(3) : | 40.1 |
| RSI | RSI(14): 63.7 |
|||
| 52-week | High : | 3.44 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BYSI ] has closed above the upper band by 12.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.2 - 2.22 | 2.22 - 2.23 |
| Low: | 1.89 - 1.91 | 1.91 - 1.92 |
| Close: | 2.18 - 2.2 | 2.2 - 2.22 |
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.
Thu, 06 Nov 2025
BeyondSpring (NASDAQ:BYSI) Trading Down 2.4% - Time to Sell? - MarketBeat
Sat, 25 Oct 2025
BeyondSpring (NASDAQ:BYSI) Receives "Sell (D)" Rating from Weiss Ratings - MarketBeat
Mon, 20 Oct 2025
Decheng capital sells BeyondSpring (BYSI) shares worth $227,675 - Investing.com
Fri, 10 Oct 2025
Decheng Capital sells BeyondSpring (BYSI) shares for $24,719 - Investing.com
Tue, 07 Oct 2025
Decheng Capital sells BeyondSpring (BYSI) shares for $35,965 - Investing.com
Tue, 16 Sep 2025
Decheng capital funds sell $7.6k in BeyondSpring (BYSI) shares - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 40 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 15.2 (%) |
| Held by Institutions | 14.1 (%) |
| Shares Short | 2,110 (K) |
| Shares Short P.Month | 2,100 (K) |
| EPS | -0.21 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -14 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -11 |
| PEG Ratio | 0 |
| Price to Book value | -2.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|